Published in Antimicrob Agents Chemother on July 01, 2006
Determinants of disease presentation and outcome during cryptococcosis: the CryptoA/D study. PLoS Med (2007) 2.85
PI3K signaling of autophagy is required for starvation tolerance and virulenceof Cryptococcus neoformans. J Clin Invest (2008) 1.45
Major role for amphotericin B-flucytosine combination in severe cryptococcosis. PLoS One (2008) 1.43
In Vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba. Antimicrob Agents Chemother (2008) 1.40
Correlation of genotype and in vitro susceptibilities of Cryptococcus gattii strains from the Pacific Northwest of the United States. J Clin Microbiol (2009) 1.35
Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole. Antimicrob Agents Chemother (2012) 1.28
Flucytosine and cryptococcosis: time to urgently address the worldwide accessibility of a 50-year-old antifungal. J Antimicrob Chemother (2013) 1.16
Polymyxin B, in combination with fluconazole, exerts a potent fungicidal effect. J Antimicrob Chemother (2010) 1.09
Combination of amphotericin B with flucytosine is active in vitro against flucytosine-resistant isolates of Cryptococcus neoformans. Antimicrob Agents Chemother (2006) 1.03
Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for amphotericin B and flucytosine. Antimicrob Agents Chemother (2012) 1.02
Trends in antifungal drug susceptibility of Cryptococcus neoformans isolates obtained through population-based surveillance in South Africa in 2002-2003 and 2007-2008. Antimicrob Agents Chemother (2011) 0.96
Calcineurin inhibitor agents interact synergistically with antifungal agents in vitro against Cryptococcus neoformans isolates: correlation with outcome in solid organ transplant recipients with cryptococcosis. Antimicrob Agents Chemother (2007) 0.94
Correlation of anti-fungal susceptibility with clinical outcomes in patients with cryptococcal meningitis. BMC Infect Dis (2012) 0.90
Microsatellite typing and susceptibilities of serial Cryptococcus neoformans isolates from Cuban patients with recurrent cryptococcal meningitis. BMC Infect Dis (2010) 0.90
In vitro-clinical correlations for amphotericin B susceptibility in AIDS-associated cryptococcal meningitis. Antimicrob Agents Chemother (2006) 0.88
Correlation of susceptibility of Cryptococcus neoformans to amphotericin B with clinical outcome. Antimicrob Agents Chemother (2011) 0.84
Pigment production on L-tryptophan medium by Cryptococcus gattii and Cryptococcus neoformans. PLoS One (2014) 0.76
Increasing trend of fluconazole-non-susceptible Cryptococcus neoformans in patients with invasive cryptococcosis: a 12-year longitudinal study. BMC Infect Dis (2015) 0.76
Physiological Differences in C. neoformans in vitro versus in vivo and Their Effects on Antifungal Susceptibility. Antimicrob Agents Chemother (2016) 0.75
Integrated therapy for HIV and cryptococcosis. AIDS Res Ther (2016) 0.75
Retrospective Study of Cryptococcal Meningitis With Elevated Minimum Inhibitory Concentration to Fluconazole in Immunocompromised Patients. Open Forum Infect Dis (2016) 0.75
Identification of QTLs Associated with Virulence Related Traits and Drug Resistance in Cryptococcus neoformans. G3 (Bethesda) (2016) 0.75
Cryptococcus neoformans and C. gattii isolates from both HIV-infected and uninfected patients: antifungal susceptibility and outcome of cryptococcal disease. Rev Inst Med Trop Sao Paulo (2017) 0.75
Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin Infect Dis (2000) 5.53
Identification of patients with acute AIDS-associated cryptococcal meningitis who can be effectively treated with fluconazole: the role of antifungal susceptibility testing. Clin Infect Dis (1996) 3.52
Has antifungal susceptibility testing come of age? Clin Infect Dis (2002) 3.39
Susceptibility testing of Cryptococcus neoformans: a microdilution technique. J Clin Microbiol (1992) 3.12
The changing epidemiology of cryptococcosis: an update from population-based active surveillance in 2 large metropolitan areas, 1992-2000. Clin Infect Dis (2003) 3.04
Interlaboratory evaluation of Etest method for testing antifungal susceptibilities of pathogenic yeasts to five antifungal agents by using Casitone agar and solidified RPMI 1640 medium with 2% glucose. J Clin Microbiol (1996) 2.53
Epidemiology of HIV-associated cryptococcosis in France (1985-2001): comparison of the pre- and post-HAART eras. AIDS (2004) 2.11
Epidemiology of cryptococcosis in France: a 9-year survey (1985-1993). French Cryptococcosis Study Group. Clin Infect Dis (1996) 2.02
Detection of resistance to amphotericin B among Cryptococcus neoformans clinical isolates: performances of three different media assessed by using E-test and National Committee for Clinical Laboratory Standards M27-A methodologies. J Clin Microbiol (1998) 1.89
Serotyping of Cryptococcus neoformans by using a monoclonal antibody specific for capsular polysaccharide. J Clin Microbiol (1993) 1.80
Correlation of fluconazole MICs with clinical outcome in cryptococcal infection. Antimicrob Agents Chemother (2000) 1.51
Cryptococcosis: clinical and biological aspects. Med Mycol (2000) 1.35
Multi-centre evaluation of the Etest method for antifungal drug susceptibility testing of Candida spp. and Cryptococcus neoformans. BSAC Working Party on Antifungal Chemotherapy. J Antimicrob Chemother (1998) 1.34
High-dose fluconazole therapy for cryptococcal meningitis in patients with AIDS. Clin Infect Dis (1996) 1.24
Prevalence of serotype D in Cryptococcus neoformans isolates from HIV positive and HIV negative patients in Italy. Mycoses (1997) 1.19
Clinical features and in vitro susceptibilities of two varieties of Cryptococcus neoformans in Taiwan. Diagn Microbiol Infect Dis (2000) 1.19
Efficacy of amphotericin B in combination with flucytosine against flucytosine-susceptible or flucytosine-resistant isolates of Cryptococcus neoformans during disseminated murine cryptococcosis. Antimicrob Agents Chemother (2006) 1.13
Drug resistance in Cryptococcus neoformans. Drug Resist Updat (1999) 1.13
Flucytosine and cryptococcosis: which in vitro test is the best predictor of outcome? J Chemother (2003) 1.09
Fluconazole susceptibility testing of Cryptococcus neoformans: comparison of two broth microdilution methods and clinical correlates among isolates from Ugandan AIDS patients. J Clin Microbiol (1998) 1.08
Fluconazole, with or without dexamethasone for experimental cryptococcosis: impact of treatment timing. J Antimicrob Chemother (1999) 1.07
In vitro interaction of flucytosine with conventional and new antifungals against Cryptococcus neoformans clinical isolates. Antimicrob Agents Chemother (2003) 1.01
Antifungal susceptibilities, varieties, and electrophoretic karyotypes of clinical isolates of Cryptococcus neoformans from Brazil, Chile, and Venezuela. J Clin Microbiol (2001) 0.96
Relationship between in vitro activities of amphotericin B and flucytosine and pH for clinical yeast and mold isolates. Antimicrob Agents Chemother (2005) 0.96
Timed-kill curves for Cryptococcus neoformans isolated from patients with AIDS. Med Mycol (2000) 0.95
Correspondence of in vitro and in vivo fluconazole dose-response curves for Cryptococcus neoformans. Antimicrob Agents Chemother (2005) 0.94
Flucytosine monotherapy for cryptococcosis. Clin Infect Dis (1998) 0.93
Biochemical serogrouping of clinical isolates of Cryptococcus neoformans. Diagn Microbiol Infect Dis (1987) 0.90
In vitro susceptibility studies of Cryptococcus neoformans isolated from patients with no clinical response to amphotericin B therapy. J Antimicrob Chemother (2000) 0.87
Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis (2001) 12.73
Incidence and risk factors of immune reconstitution inflammatory syndrome complicating HIV-associated cryptococcosis in France. AIDS (2005) 5.51
ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect (2012) 4.56
Ezrin contains cytoskeleton and membrane binding domains accounting for its proposed role as a membrane-cytoskeletal linker. J Cell Biol (1993) 3.96
Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest (2007) 3.58
Hybrid genotypes in the pathogenic yeast Cryptococcus neoformans. Microbiology (2001) 3.27
Mediastinitis due to multiple resistant Corynebacterium xerosis. Clin Infect Dis (1993) 3.14
Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum (2009) 2.92
Determinants of disease presentation and outcome during cryptococcosis: the CryptoA/D study. PLoS Med (2007) 2.85
Epidemiological evidence for dormant Cryptococcus neoformans infection. J Clin Microbiol (1999) 2.78
Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. Medicine (Baltimore) (1996) 2.72
Acquired itraconazole resistance in Aspergillus fumigatus. J Antimicrob Chemother (2001) 2.69
Protection of mice against experimental cryptococcosis by anti-Cryptococcus neoformans monoclonal antibody. Infect Immun (1987) 2.63
Production, characterization, and antibody specificity of a mouse monoclonal antibody reactive with Cryptococcus neoformans capsular polysaccharide. Infect Immun (1987) 2.61
Ezrin is an effector of hepatocyte growth factor-mediated migration and morphogenesis in epithelial cells. J Cell Biol (1997) 2.51
ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013. Clin Microbiol Infect (2014) 2.47
Morphogenic effects of ezrin require a phosphorylation-induced transition from oligomers to monomers at the plasma membrane. J Cell Biol (2000) 2.45
Escherichia coli native valve endocarditis. Clin Microbiol Infect (2006) 2.28
Antifungal drug resistance in pathogenic fungi. Med Mycol (1998) 2.28
Ezrin is a downstream effector of trafficking PKC-integrin complexes involved in the control of cell motility. EMBO J (2001) 2.27
Ezrin, a plasma membrane-microfilament linker, signals cell survival through the phosphatidylinositol 3-kinase/Akt pathway. Proc Natl Acad Sci U S A (1999) 2.21
Waterborne outbreak of intestinal microsporidiosis in persons with and without human immunodeficiency virus infection. J Infect Dis (1999) 2.20
Villin induces microvilli growth and actin redistribution in transfected fibroblasts. Cell (1989) 2.19
Tuberculosis in HIV-infected patients: a comprehensive review. Clin Microbiol Infect (2004) 2.13
Epidemiology of HIV-associated cryptococcosis in France (1985-2001): comparison of the pre- and post-HAART eras. AIDS (2004) 2.11
A global analysis of mucormycosis in France: the RetroZygo Study (2005-2007). Clin Infect Dis (2012) 2.07
Cytoskeletal rearrangements and the functional role of T-plastin during entry of Shigella flexneri into HeLa cells. J Cell Biol (1995) 2.06
ESCMID and ECMM joint clinical guidelines for the diagnosis and management of rare invasive yeast infections. Clin Microbiol Infect (2014) 2.06
Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis (2004) 2.06
Enterocytozoon bieneusi as a cause of chronic diarrhea in a heart-lung transplant recipient who was seronegative for human immunodeficiency virus. Clin Infect Dis (1996) 1.98
The junction-associated protein, zonula occludens-1, localizes to the nucleus before the maturation and during the remodeling of cell-cell contacts. Proc Natl Acad Sci U S A (1996) 1.95
A small rab GTPase is distributed in cytoplasmic vesicles in non polarized cells but colocalizes with the tight junction marker ZO-1 in polarized epithelial cells. J Cell Biol (1994) 1.80
Multicenter evaluation of the reproducibility of the proposed antifungal susceptibility testing method for fermentative yeasts of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antimicrobial Susceptibility Testing (AFST-EUCAST). Clin Microbiol Infect (2003) 1.79
Haemophilus endocarditis: report of 42 cases in adults and review. Haemophilus Endocarditis Study Group. Clin Infect Dis (1997) 1.75
Primary cutaneous cryptococcosis: a distinct clinical entity. Clin Infect Dis (2003) 1.74
Cas1p is a membrane protein necessary for the O-acetylation of the Cryptococcus neoformans capsular polysaccharide. Mol Microbiol (2001) 1.74
Disseminated Scedosporium prolificans (S. inflatum) infection after single-lung transplantation. Clin Infect Dis (1994) 1.72
ESCMID and ECMM joint guidelines on diagnosis and management of hyalohyphomycosis: Fusarium spp., Scedosporium spp. and others. Clin Microbiol Infect (2014) 1.70
Unipolar reorganization of F-actin layer at bacterial division and bundling of actin filaments by plastin correlate with movement of Shigella flexneri within HeLa cells. Infect Immun (1992) 1.63
The membrane-microfilament linker ezrin is involved in the formation of the immunological synapse and in T cell activation. Immunity (2001) 1.61
Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry. Ann Rheum Dis (2010) 1.59
In-vitro susceptibility of Aspergillus spp. isolates to amphotericin B and itraconazole. J Antimicrob Chemother (1999) 1.58
Epidemiological trends in invasive aspergillosis in France: the SAIF network (2005-2007). Clin Microbiol Infect (2011) 1.55
ESCMID* guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT). Clin Microbiol Infect (2012) 1.55
Community-acquired pneumonia. Importance of initial noninvasive bacteriologic and radiographic investigations. Chest (1988) 1.55
Streptococcus pneumoniae endocarditis in adults. A multicenter study in France in the era of penicillin resistance (1991-1998). The Pneumococcal Endocarditis Study Group. Medicine (Baltimore) (2000) 1.50
ESCMID* guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp. Clin Microbiol Infect (2012) 1.48
Ezrin function is required for ROCK-mediated fibroblast transformation by the Net and Dbl oncogenes. EMBO J (2000) 1.47
In vitro synthesis and posttranslational uptake of cytochrome c into isolated mitochondria: role of a specific addressing signal in the apocytochrome. Proc Natl Acad Sci U S A (1981) 1.47
Spot position of rat liver ribosomal proteins by four different two-dimensional electrophoreses in polyacrylamide gel. Mol Gen Genet (1979) 1.44
Major role for amphotericin B-flucytosine combination in severe cryptococcosis. PLoS One (2008) 1.43
Biosynthesis and intracellular sorting of growth hormone-viral envelope glycoprotein hybrids. J Cell Biol (1985) 1.42
ESCMID* guideline for the diagnosis and management of Candida diseases 2012: diagnostic procedures. Clin Microbiol Infect (2012) 1.41
In-vivo itraconazole resistance of Aspergillus fumigatus in systemic murine aspergillosis. EBGA Network. European research group on Biotypes and Genotypes of Aspergillus fumigatus. J Med Microbiol (1999) 1.39
[Management of systemic candidiasis]. Presse Med (1999) 1.39
[Systemic granulomatosis of infectious origin]. Rev Med Interne (2007) 1.38
ESCMID and ECMM joint clinical guidelines for the diagnosis and management of systemic phaeohyphomycosis: diseases caused by black fungi. Clin Microbiol Infect (2014) 1.36
Src-dependent ezrin phosphorylation in adhesion-mediated signaling. Mol Biol Cell (2005) 1.35
A human villin cDNA clone to investigate the differentiation of intestinal and kidney cells in vivo and in culture. EMBO J (1986) 1.35
Polyarteritis nodosa related to hepatitis B virus. A prospective study with long-term observation of 41 patients. Medicine (Baltimore) (1995) 1.35
Cryptococcosis: clinical and biological aspects. Med Mycol (2000) 1.35
Molecular and idiotypic analysis of antibodies to Cryptococcus neoformans glucuronoxylomannan. Infect Immun (1994) 1.34
Improved detection of amphotericin B-resistant isolates of Candida lusitaniae by Etest. J Clin Microbiol (2001) 1.32
From the structure to the function of villin, an actin-binding protein of the brush border. Bioessays (1990) 1.29
Intestinal microsporidiosis occurring in two renal transplant recipients treated with mycophenolate mofetil. Transplantation (1999) 1.27
Comparative in vitro activities of caspofungin and micafungin, determined using the method of the European Committee on Antimicrobial Susceptibility Testing, against yeast isolates obtained in France in 2005-2006. Antimicrob Agents Chemother (2007) 1.26
Fluconazole for the management of invasive candidiasis: where do we stand after 15 years? J Antimicrob Chemother (2006) 1.26
Partial deduced sequence of the 110-kD-calmodulin complex of the avian intestinal microvillus shows that this mechanoenzyme is a member of the myosin I family. J Cell Biol (1989) 1.23
Molecular recognition between serine proteases and new bioactive microproteins with a knotted structure. Biochimie (1991) 1.23
Evaluation of a monoclonal antibody-based latex agglutination test for diagnosis of cryptococcosis: comparison with two tests using polyclonal antibodies. J Clin Microbiol (1992) 1.20
Evaluation of a flow cytofluorometric method for rapid determination of amphotericin B susceptibility of yeast isolates. Antimicrob Agents Chemother (1997) 1.20
Diagnostic contribution of positron emission tomography with [18F]fluorodeoxyglucose for invasive fungal infections. Clin Microbiol Infect (2011) 1.20
Fusarium infections in immunocompromised patients: case reports and literature review. Eur J Clin Microbiol Infect Dis (1994) 1.20
Rapid detection of Pneumocystis carinii in bronchoalveolar lavage specimens from human immunodeficiency virus-infected patients: use of a simple DNA extraction procedure and nested PCR. J Clin Microbiol (1997) 1.20
Amphotericin B resistance of Aspergillus terreus in a murine model of disseminated aspergillosis. J Med Microbiol (2000) 1.17
Ezrin interacts with focal adhesion kinase and induces its activation independently of cell-matrix adhesion. J Biol Chem (2001) 1.17
Gentamicin, netilmicin, dibekacin, and amikacin nephrotoxicity and its relationship to tubular reabsorption in rabbits. Antimicrob Agents Chemother (1984) 1.15
Genetic polymorphism of Aspergillus fumigatus in clinical samples from patients with invasive aspergillosis: investigation using multiple typing methods. J Clin Microbiol (2001) 1.15
Na(+)/H(+) exchanger 3 is in large complexes in the center of the apical surface of proximal tubule-derived OK cells. Am J Physiol Cell Physiol (2002) 1.15
Cryptococcal neuroradiological lesions correlate with severity during cryptococcal meningoencephalitis in HIV-positive patients in the HAART era. PLoS One (2008) 1.14
Ezrin-dependent promotion of glioma cell clonogenicity, motility, and invasion mediated by BCL-2 and transforming growth factor-beta2. J Neurosci (2001) 1.14
Molecular phylogeny and proposal of two new species of the emerging pathogenic fungus Saksenaea. J Clin Microbiol (2010) 1.13
Native valve endocarditis caused by Staphylococcus capitis. Eur J Clin Microbiol Infect Dis (1993) 1.13
Host and bacterial determinants of initial severity and outcome of Escherichia coli sepsis. Clin Microbiol Infect (2007) 1.13
A multicentre study of antifungal strategies and outcome of Candida spp. peritonitis in intensive-care units. Clin Microbiol Infect (2010) 1.13
Acute myeloid leukaemia in human immunodeficiency virus-infected adults: epidemiology, treatment feasibility and outcome. Br J Haematol (2001) 1.13
Polymicrobial pyomyositis and bacteremia in a patient with AIDS. Clin Infect Dis (1994) 1.12
Microsporidiosis in solid organ transplant recipients: two Enterocytozoon bieneusi cases and review. Transpl Infect Dis (2008) 1.11
Alternative identification test relying upon sexual reproductive abilities of Candida lusitaniae strains isolated from hospitalized patients. J Clin Microbiol (2001) 1.11
Emergence of Legionella pneumophila pneumonia in patients receiving tumor necrosis factor-alpha antagonists. Clin Infect Dis (2006) 1.11
Administration of endotoxin associated with lipopolysaccharide tolerance protects mice against fungal infection. Infect Immun (2000) 1.10
A functional role for ezrin during Shigella flexneri entry into epithelial cells. J Cell Sci (1999) 1.10
Use of voriconazole in a patient with aspergilloma caused by an itraconazole-resistant strain of Aspergillus fumigatus. J Med Microbiol (2006) 1.09